⁍ 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends ⁍ Provide Chapter-wise guidance on Requests. ⁍ 100+ Pages Research Report (Inclusion of Updated Research). ⁍ 2030 Updated Report Introduction, Overview, and In-depth industry analysis. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.) (The sample of this report is readily available on request. They are particularly valuable in situations where timely diagnostic information is essential for effective patient management, treatment decisions, and infection control measures.Īsk Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis Rapid diagnostics play a critical role in various healthcare settings, including hospitals, clinics, emergency departments, and point-of-care settings. These tests are specifically developed to deliver rapid and on-the-spot diagnostic information, allowing healthcare professionals to make immediate decisions regarding patient care. Rapid diagnostics refers to a category of medical tests and devices that are designed to provide quick and timely results, often within a short span of time. There are market research studies and procedures that are deliberately planned to capture useful data to guide every decision, and they must take into account all the relevant elements. Coherent Market Insight has released a new research study titled Rapid Diagnostics Market is growing rapidly, which signifies a strong interest in Rapid Diagnostics research as we enter 2023.īusiness executives nowadays must make countless decisions on distribution routes, pricing, target markets, promotions, and the features and advantages of their products. Abbott is also in the process of developing reagents for further studies, and is exploring collaborations with pharmaceutical companies to leverage the FGFR3 test as a companion diagnostic for emerging bladder cancer therapies.įor more information, visit Abbott Molecular.Rapid diagnostic tests are easy-to-use tests that provide quick results, usually 30 in minutes or less.īURLINGAME, CA, UNITED STATES, June 14, 2023/ / - Rapid Diagnostics Market Size Projections : The global rapid diagnostics market was valued at US$ 33.4 Bn in 2022 and is forecast to reach a value of US$ 70.27 Bn by 2030 at a CAGR of 9.8% between 20. The FGFR3 mutation analysis assay will be available in early 2015. “FGFR3 mutations have a broad clinical utility-including early detection, disease monitoring, and predicting patient outcomes-which offers an opportunity for doctors to help improve bladder cancer patient outcomes and quality of life,” says Michael Cookson, MD, chairman of the department of urology at the University of Oklahoma College of Medicine and a member of the scientific advisory board for the Bladder Cancer Advocacy Network.Ībbott currently offers the only FDA-approved urine-based molecular test for bladder cancer, UroVysion, which is included in the National Comprehensive Cancer Network and European Association of Urology guidelines. Currently, 9 in 10 patients with stage 1 bladder cancer live 5 years or longer. About 75,000 new cases of bladder cancer are diagnosed in the United States each year, but many patients in stages 0 to 2 can be treated successfully with surgery and chemotherapy. “Our agreement helps Institut Curie optimize the clinical utility of FGFR3, and we are looking forward to combining our strengths with Abbott to create a diagnostic to help improve care for bladder cancer patients.”Īctivating FGFR3 gene mutations are seen in about 70% of low-grade and 15 to 20% of high-grade bladder cancer cases, making them useful biomarkers to assist in early detection. “We are pleased to partner with Abbott given their deep expertise in molecular and companion diagnostics,” says Damien Salauze, vice president of business development and licensing at Institut Curie. Institut Curie has assigned exclusive rights to FGFR3 gene mutations for use in detecting bladder cancer to Abbott Molecular, allowing the company to expand its market presence in molecular diagnostics and bladder cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |